Want to see CUPR full AI Analyst Report?
Top Page
Cuprina Holdings (Cayman) Limited Class A
(NASDAQ:CUPR)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▼(-28.32% Downside)
Action:Reiterated
Date:10/01/26
The score is driven primarily by weak financial performance—persistent losses and worsening 2025 margins alongside a sharp increase in cash burn. Technical indicators add pressure with the stock trading below key moving averages and a negative MACD. Valuation provides limited support due to a negative P/E and no dividend yield.
Positive Factors
Strategic clinic acquisition
The proposed acquisition could add an EBITDA-positive operating platform to Cuprina, broaden its healthcare footprint, and align with wound-care and collagen technologies. If completed, the clinics may provide greater revenue scale and a more diversified base for regional expansion.
Negative Factors
Persistent cash burn
Continued negative operating and free cash flow means the business is not currently self-funding its operations or investments. The sharp deterioration in 2025 increases dependence on external capital, raises funding risk, and could constrain expansion if financing becomes less available.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic clinic acquisition
The proposed acquisition could add an EBITDA-positive operating platform to Cuprina, broaden its healthcare footprint, and align with wound-care and collagen technologies. If completed, the clinics may provide greater revenue scale and a more diversified base for regional expansion.
Read all positive factors
Cuprina Holdings (Cayman) Limited Class A (CUPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.78M
Dividend YieldN/A
Average Volume (3M)149.53K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth6.30%
EPS Growth-208.64%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,891,506
10 Day Avg. Volume201,461
30 Day Avg. Volume149,530
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.08
Price to Sales (P/S)211.01
P/FCF Ratio-1.15
Enterprise Value/Market Cap1.21M
Enterprise Value/Revenue579.61M
Enterprise Value/Gross Profit-941.13M
Enterprise Value/Ebitda-5.52M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cuprina Holdings (Cayman) Limited Class A Business Overview & Revenue Model
Company Description
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its ...
Cuprina Holdings (Cayman) Limited Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.89K | 48.32K | 100.77K | 56.60K | 58.50K |
| Gross Profit | -645.00 | -3.02K | 36.60K | 19.98K | 23.06K |
| EBITDA | -4.56M | -1.43M | -994.12K | -1.06M | -489.44K |
| Net Income | -4.67M | -1.56M | -1.12M | -1.09M | -519.69K |
Balance Sheet | |||||
| Total Assets | 8.50M | 1.75M | 1.59M | 1.44M | 953.05K |
| Cash, Cash Equivalents and Short-Term Investments | 3.12M | 116.47K | 35.26K | 564.58K | 767.29K |
| Total Debt | 482.72K | 254.79K | 121.82K | 183.63K | 170.03K |
| Total Liabilities | 3.45M | 6.20M | 4.48M | 3.21M | 1.64M |
| Stockholders Equity | 5.06M | -4.46M | -2.90M | -1.78M | -683.52K |
Cash Flow | |||||
| Free Cash Flow | -9.19M | -1.26M | -1.61M | -1.87M | -224.72K |
| Operating Cash Flow | -9.13M | -1.24M | -1.54M | -1.85M | -221.86K |
| Investing Cash Flow | -58.23K | -21.88K | -67.98K | -31.28K | -2.86K |
| Financing Cash Flow | 12.23M | 1.34M | 1.08M | 1.68M | 991.39K |
Cuprina Holdings (Cayman) Limited Class A Technical Analysis
Negative
2.79
Price Trends
2.69
Negative
3.27
Negative
3.17
Negative
Market Momentum
-0.18
Negative
40.70
Neutral
32.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUPR, the sentiment is Negative. The current price of 2.79 is above the 20-day moving average (MA) of 2.23, above the 50-day MA of 2.69, and below the 200-day MA of 3.17, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 40.70 is Neutral, neither overbought nor oversold. The STOCH value of 32.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUPR.
Cuprina Holdings (Cayman) Limited Class A Risk Analysis
Cuprina Holdings (Cayman) Limited Class A disclosed 69 risk factors in its most recent earnings report. Cuprina Holdings (Cayman) Limited Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cuprina Holdings (Cayman) Limited Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $12.78M | -1.38 | -1569.05% | ― | 6.30% | -208.64% | |
42 Neutral | $3.51M | -0.03 | -142.16% | ― | 707.02% | 70.52% | |
42 Neutral | $3.75M | -0.02 | -372.86% | ― | ― | 53.95% | |
39 Underperform | $2.91M | -0.02 | -743.66% | ― | -100.00% | 77.63% |
* Healthcare Sector Average
CUPR
Cuprina Holdings (Cayman) Limited Class A
1.99
-6.97
-77.79%
GOVX
GeoVax Labs
0.29
-14.28
-98.02%
HCWB
HCW Biologics
1.56
-27.72
-94.67%
CLDI
Calidi Biotherapeutics
1.01
-24.43
-96.03%
PBM
Psyence Biomedical
4.88
-22.87
-82.41%
ASBP
Aspire Biopharma Holdings
8.63
-428.53
-98.03%
Cuprina Holdings (Cayman) Limited Class A Corporate Events
Cuprina Holdings to Acquire Profitable Singapore Podiatry and Women’s Health Clinic Group
Oct 2, 2026
On October 1, 2026, Cuprina’s wholly owned BVI subsidiary signed agreements to acquire all shares of East Coast Podiatry Centre and Orchard Clinic Management for about S$4.0 million, via a mix of cash and Class A shares subject to lock-ups. ...
Cuprina Holdings Closes Over-Allotment Option, Lifts Public Offering Proceeds to $5.7 Million
Sep 29, 2026
On September 29, 2026, Cuprina Holdings (Cayman) Limited closed the sale of 648,373 additional Class A ordinary shares at $1.15 per share, following the full exercise of the underwriter’s over-allotment option tied to its recent Nasdaq publi...
Cuprina Holdings Calls October EGM to Approve Major Share Capital Increase and Governance Changes
Sep 18, 2026
On September 18, 2026, Cuprina Holdings (Cayman) Limited filed a Form 6-K with the U.S. SEC announcing an extraordinary general meeting of shareholders scheduled for October 15, 2026 in Singapore and via webcast. Shareholders of record as of Septe...
Cuprina Holdings Raises $4.97 Million in September Nasdaq Offering
Sep 18, 2026
On September 15, 2026, Cuprina Holdings (Cayman) Limited entered into an underwriting agreement with R. F. Lafferty Co., Inc. for a Nasdaq-listed public offering of 4,322,489 Class A ordinary shares at $1.15 per share, raising gross proceeds of a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.